UNIT 6-10, ZEUS BUILDING, DIDCOT, X0
To Combine with to Target Metabolic and Autoimmune Diseases
Amended material disclosure
Earnings Release
Shareholder votes
Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
Annual Report to Security Holders
Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Investor Presentation
Q2
Q1
FY 2024
FY 2023
Q3
Prospectus Filed Pursuant to Rule 425
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement
SEC Staff Correspondence